

2020 Statement of Financial Position

Phoenix Bioinformatics Corporation
As of December 31, 2020

Prepared by Connie NG

2020 Statement of Financial Position

Phoenix Bioinformatics Corporation

As of December 31, 2020

Accrual Basis

DEC 31, 2020

Assets

Current Assets

Cash and Cash Equivalents

BioCyc Account Citibank	230,482
Incoming Funds Citibank	196,721
Operations Citibank	320,218
Schwab Cash Account	714
Schwab Investment Account	872,932
RepBase Account Citibank	63,153
CIPRES Account Citibank	7,906
MorphoBank Account Citibank	9,232
Total Cash and Cash Equivalents	1,701,356

Accounts Receivable	575,669
Prepaid Expenses	18,308
Total Current Assets	2,295,334

Fixed Assets

Database and Software	1,561,361
Accum Depr - Database and Software	(991,858)
Computer Equipment	23,193
Accum Depr - Computer Equipment	(16,045)
Total Fixed Assets	576,650

Long Term Assets

Security Deposits Asset	5,576
Total Long Term Assets	5,576

Total Assets	2,877,560
---------------------	------------------

Liabilities and Net Assets

Liabilities

Current Liabilities

Accounts Payable	5,010
Accrued Employee Benefit Expenses	(294)
Accrued Expense CalChoice	(289)
Accrued Leave	103,271
Accrued Earned BioCyc Revenue Payable to SRI	77,772
BioCyc Unearned Revenue	306,883
Unearned or Deferred Revenue	990,155
Accrued Earned RepBase Revenue Payable to GIRI	24,413
RepBase Unearned Revenue	82,177
MorphoBank Unearned Revenue	11,050

DEC 31, 2020

Accrued Earned MorphoBank Revenue to RFSUNY	3,877
Capital One Credit Card	5,654
Total Current Liabilities	1,609,678
Total Liabilities	1,609,678
Net Assets	
Unrestricted	
Undesignated	1,241,882
Operating Reserve Fund	26,000
Total Unrestricted	1,267,882
Total Net Assets	1,267,882
Total Liabilities and Net Assets	2,877,560

2020 Statement of Activities

Phoenix Bioinformatics Corporation For the year ended December 31, 2020 Accrual Basis

	UNRESTRICTED	TEMPORARILY RESTRICTED	TOTAL
Income			
Program Service Fees	86,625	-	86,625
Consulting Services	28,926	-	28,926
Foundation and Trust Grants	495,184	-	495,184
Individ, Business Contributions	11,565	-	11,565
BioCyc Subscription Revenue	63,408	-	63,408
Program Subscriptions - TAIR			
Subscription - Country and Consortiums	351,670	-	351,670
Corporate	122,360	-	122,360
Nonprofit and Academic	659,307	-	659,307
Individual and Lab	33,722	-	33,722
Total Program Subscriptions - TAIR	1,167,059	-	1,167,059
Wire Transfer Service Charge	4,184	-	4,184
RepBase Subscription Revenue	19,835	-	19,835
AgBase Subscription Revenue	44	-	44
Total Income	1,876,832	-	1,876,832
Cost of Goods Sold			
Subaward Expenses	130,433	-	130,433
Total Cost of Goods Sold	130,433	-	130,433
Operating Expenses			
Employee Costs			
Salaries and Wages	1,315,356	-	1,315,356
Vacation Expense	38,743	-	38,743
Payroll Taxes	97,721	-	97,721
Employee Benefits	73,584	-	73,584
401k Plan Contributions	97,849	-	97,849
Staff Development	545	-	545
Worker's Compensation Insurance	953	-	953
Total Employee Costs	1,624,752	-	1,624,752
Software Licenses & Services	59,414	-	59,414
Meeting and Travel			
Board-Related Expenses	480	-	480
Conference, Convention, Meeting	2,050	-	2,050
Travel	4,085	-	4,085
Total Meeting and Travel	6,614	-	6,614
Facilities and Equipment	74,918	-	74,918
Professional Fees	12,176	-	12,176
Insurance - Liability, D and O	519	-	519

	UNRESTRICTED	TEMPORARILY RESTRICTED	TOTAL
Subscriptions and References	698	-	698
Office Supplies	2,097	-	2,097
License and Registration Fees	351	-	351
Transaction and Wire Fees	6,137	-	6,137
Audit & Tax Preparation Fees	3,775	-	3,775
WFH Stipends	975	-	975
Total Operating Expenses	1,792,427	-	1,792,427
Operating Income	(46,028)	-	(46,028)
Other Income / (Expense)			
Depreciation Expense	(175,583)	-	(175,583)
Capitalized PhyloGenes Software Dev.	160,694	-	160,694
Credit Card Rebates	1,200	-	1,200
Interest Expense	(82)	-	(82)
Interest-Savings, Short-term CD	-	-	-
Interest and Dividends Earned (Investments)	13,515	-	13,515
Unrealized Gain (Loss) on Investments	52,715	-	52,715
Total Other Income / (Expense)	52,460	-	52,460
Increase (Decrease) in Net Assets	6,432	-	6,432

Statement of Cash Flows

Phoenix Bioinformatics Corporation For the year ended December 31, 2020

2020

Cash Flows from Operating Activities

Receipts from customers	209,307
Payments to suppliers and employees	(1,565,729)
Cash receipts from other operating activities	13,515
Total Cash Flows from Operating Activities	(1,342,906)

Cash Flows from Investing Activities

Proceeds from sale of property, plant and equipment	14,846
Payment for property, plant and equipment	(321,448)
Other cash items from investing activities	(46,615)
Total Cash Flows from Investing Activities	(353,216)

Cash Flows from Financing Activities

Other cash items from financing activities	1,855,903
Total Cash Flows from Financing Activities	1,855,903

Net Cash Flows	159,780
-----------------------	----------------

Cash Balances

Cash and cash equivalents at beginning of period	668,645
Cash and cash equivalents at end of period	828,425
Net change in cash for period	159,780